Capricor Therapeutics Inc. announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to discuss positive topline results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). The webinar is scheduled for December 17, 2025, and will provide an overview of the HOPE-3 results and their implications for ongoing regulatory discussions, including next steps with the U.S. Food and Drug Administration (FDA). The topline results from the study have already been presented and will be further discussed during the upcoming webinar. A replay will be available on the PPMD website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603271) on December 16, 2025, and is solely responsible for the information contained therein.